



Product Information

MONOCLONAL ANTI-MDM2 CLONE SMP14 Mouse Ascites Fluid

Product Number **M 4308**

Product Description

Monoclonal Anti-MDM2 (mouse IgG1 isotype) is derived from the SMP14 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from a BALB/c mouse immunized with a synthetic peptide corresponding to amino acids 154-167 of human MDM2, conjugated to KLH.¹ The isotype is determined using Sigma ImmunoType™ Kit (Product Code ISO-1) and by a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents (Product Code ISO-2).

Monoclonal Anti-MDM2 recognizes an epitope within amino acids 154-167 of human MDM2.¹ The antibody detects the MDM2 protein alone or in complex with E2F1, p53 and retinoblastoma proteins. A slight cross-reactivity is observed with cytokeratins 6, 14 and 16. The antibody may be used for ELISA,¹ immunoblotting¹⁻³ (90 kDa and additional weak doublet of approx. 55 kDa), immunoprecipitation,¹ immunocytochemistry (predominantly nuclear and some cytoplasmic staining), and immunohistochemistry (acetone-fixed, frozen and formalin-fixed paraffin-embedded sections). Species cross-reactivity has been observed with human,²⁻³ rat,¹ and mouse³ (weak) MDM2.

Inactivation of tumor-suppressor gene p53, leads to deregulated cell proliferation and is a key factor in human tumorigenesis. The ability of p53 to either restrain or kill a cell must be reigned in under normal conditions. Several cell genes have been identified whose expression is activated by p53. One of these, the *mdm2* gene, originally found on mouse double minute chromosomes, encodes a protein that interacts directly with p53 and negatively regulates p53 transcriptional activity. p53 and MDM2 (the human homologue of Mdm2, a 90 kDa molecule), function in mutual regulation; activation of p53 results in expression of MDM2, which consequently inhibits p53 transcriptional function.⁴ MDM2 accomplishes this inhibition in two ways: as a result of its physical interaction with p53, MDM2 both represses p53 transcriptional activity and mediates the degradation of

p53.⁵ Overexpression of MDM2 results in reduced quantities of coexpressed p53, and disruption of the p53-MDM2 interaction by mutation results in both activation and accumulation of p53.⁶ The region on p53 with which MDM2 interacts (residues 17-27) is one of the segments of p53 that is highly conserved not only among different species, but even among some p53-related family members, such as p73. In addition, this portion of p53 is located within the transcriptional activation region, which is required for the interaction of p53 with components of the general transcriptional machinery, such as TAFs. A number of phosphorylation sites have been identified in the vicinity of this region, they are highly likely to be involved in regulating p53. Indeed, MDM2 needs to bind to the p300 transcriptional coactivator/histone acetylase in order to mediate degradation of p53. It has also been shown that MDM2 shuttles p53 from the nucleus to the cytoplasm where it is then degraded.⁷ One way to stabilize and activate p53 in cells is by interfering either with the interaction between MDM2 and p53 or with the ability of MDM2 to target bound p53 for degradation. p53-MDM2 interaction may be regulated through two entirely separated and independent mechanisms, which are regulated through distinct signaling pathways: changes in p53 due to covalent modification, and/or through noncovalent regulators of the p53-MDM2 association. Thus, DNA damage-induced phosphorylation of p53 can attenuate the p53-MDM2 interaction, and the product of the alternate reading frame (ARF) located within the p16^{INK4A} locus (murine p19^{ARF}, human p14^{ARF}) can bind to MDM2 and prevent its destruction of p53. It is well established that MDM2 is itself a transcriptional target of p53 that is induced after p53 becomes stabilized and activated; by interacting with MDM2 and inhibiting ARF expression, p53 levels are kept low during normal conditions. After stress, modification of the p53 protein prevents or disrupts the p53-MDM2 interaction, while as a result of oncogene imbalance, ARF is induced and MDM2 is prevented from destabilizing p53. The outcome in both cases though, is increased levels and activation of p53 protein. In addition to its relationships with p53, MDM2 protein has been shown to activate cell proliferation by

stimulating the S-phase-inducing transcription factors, E2F1/DP1. The amplification of the MDM2 gene has been demonstrated in various human neoplasms.⁸ MDM2 is frequently overexpressed in the nuclei of soft-tissue sarcomas, and to a much lesser extent in a wide variety of malignancies, such as bladder, breast, testes, and cervix cancers, and in glial cells, and a range of hematological disorders. Monoclonal antibody reacting specifically with MDM2 is an essential tool in defining the interactions and distributions of MDM2, its function in signaling pathways and in mutual regulation of p53.

Reagents

Monoclonal Anti-MDM2 is supplied as ascites fluid containing 15 mM sodium azide.

Precautions and Disclaimer

Due to the sodium azide content a material safety sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazardous and safe handling practices.

Storage/Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended.

Storage in "frost-free" freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

A minimum working dilution of 1:1,000 is determined by immunoblotting using a whole extract of transfected 293T (human embryonal kidney) cells, expressing human MDM2.

Note: In order to obtain best results in different techniques and preparations we recommend determining optimal working dilution by titration test.

References

1. Picksley, S.M., et al., *Oncogene*, **9**, 2523 (1994).
2. Hickman, E.S., et al., *Oncogene*, **9**, 2177 (1994).
3. Martin, K., et al., *Nature*, **375**, 691 (1995).
4. Fakharzadeh, S.S., et al., *EMBO J.*, **10**, 1565 (1991).
5. Prives, C., *Cell*, **95**, 5 (1998).
6. Haupt, Y., et al., *Nature*, **387**, 296 (1997).
7. Roth, J., et al., *EMBO J.*, **17**, 554 (1998).
8. Xiao, Z.-X., et al., *Nature*, **375**, 694 (1995).

lpg 3/00

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.